Author:
Van Coillie Julie,Schulz Morten A.,Bentlage Arthur E. H.,de Haan Noortje,Ye Zilu,Geerdes Dionne M.,van Esch Wim J. E.,Hafkenscheid Lise,Miller Rebecca L.,Narimatsu Yoshiki,Vakhrushev Sergey Y.,Yang Zhang,Vidarsson Gestur,Clausen Henrik
Abstract
Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system. The conservedN-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities. Studies have suggested that alsoN-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinctN-glycans have been hindered by the natural heterogeneity inN-glycosylation. In this study, we employed comprehensive genetic engineering of theN-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with differentN-glycan structures to more generally explore the role ofN-glycosylation in IgG1:FcγRIIIa binding interactions. We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the keyN-glycan features that affected binding affinity. Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
Subject
Immunology,Immunology and Allergy